(Q36659824)

15 August 2017

1 reference

title

Alemtuzumab in CLL and other lymphoid neoplasms (English)

1 reference

15 August 2017

1

Farhad Ravandi

1 reference

15 August 2017

2

Susan O'brien

1 reference

15 August 2017

publication date

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

7

1 reference

15 August 2017

page(s)

718-725

1 reference

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Monoclonal antibody therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Novel immune-based treatment strategies for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Primary structure of CD52.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Pharmacokinetics of CAMPATH-1H: assay development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

The evolving role of alemtuzumab in management of patients with CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

CD52 expression in hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

CD52 is not a promising immunotherapy target for most patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600981414

10.1080/07357900600981414

21 January 2018

Identifiers

DOI

1 reference

release_tj6strrzwraehisaygad4dbtym

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tj6strrzwraehisaygad4dbtym

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference